CORONA
CORONA Remedies Limited (CORONA) Stock Analysis
CORONA Remedies Limited is an Indian pharmaceutical company marketing formulations. It sells medicines in select therapeutic areas through distributors and doctors in India. Brand building and field force productivity support domestic growth. The company is listed on Indian stock exchanges and operates from India.
Healthcare › Drug Manufacturers - General
₹2,024.00
-0.27% 1W | +41.90% 52W
Market Cap
–
P/E Ratio
62.2
52W High
₹2292.4
52W Low
₹1336.6
Div. Yield
0.5%
Beta
–
50 DMA
₹2115.9
200 DMA
₹1781.4
Profit Margin
13.5%
Inst. Own.
13.9%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other Income | 2 | 1 | 2 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 44 | 61 | 70 | 55 | 55 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net Profit | 43 | 45 | 32 | 46 | 52 | 41 | 45 | 60 |
| EPS in Rs | 7.03 | 7.35 | 5.16 | 7.55 | 8.55 | 6.75 | 7.41 | 9.83 |
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Expenses | 756 | 859 | 956 | 1,109 | 1,162 |
| Operating Profit | 128 | 156 | 241 | 294 | 317 |
| OPM % | 14% | 15% | 20% | 21% | 21% |
| Other Income | 7 | 5 | 6 | -9 | -7 |
| Interest | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 20 | 28 | 37 | 38 | 42 |
| Profit before tax | 111 | 118 | 199 | 240 | 260 |
| Tax % | 23% | 24% | 25% | 23% | |
| Net Profit | 85 | 90 | 149 | 185 | 199 |
| EPS in Rs | 13.89 | 14.80 | 24.43 | 30.27 | 32.54 |
| Dividend Payout % | 20% | 25% | 30% | 33% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 17.0% | – | – |
| Profit CAGR | 33.0% | – | – |
Shareholding Pattern
Promoters69.00%
FIIs1.84%
DIIs6.77%
Public22.41%
Promoters69.00%
FIIs2.25%
DIIs7.02%
Public21.75%
Promoters69.00%
FIIs3.63%
DIIs12.90%
Public14.47%
Promoters69.00%
FIIs2.25%
DIIs7.02%
Public21.75%
Promoters69.00%
FIIs3.63%
DIIs12.90%
Public14.47%
CORONA
Holdings Analysis
Key strengths & risk signals
76
Overall
77
Fundamental
75
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.5% yield - little to no income.
RECOVERY MODE! Current price (2024.0) above 200-day but below 50-day.
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.3% (1 week), 7.9% (1 month), 0.9% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (2115.9) is above 200-day average (1781.4) - positive signal.
GOOD YEAR! Stock gained 41.9% in the last year.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 63,253 vs down days: 23,550. Ratio: 2.69x
Fundamental & Technical Analysis
76Overall
77Fundamental
75Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 16.6% (VERY GOOD, 13/15). Profit CAGR: 29.7% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.5% profit margin - acceptable profitability.
PEG Valuation
7/10
OVERVALUED! PEG of 2.09 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.5% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.14 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 22.41% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2115.9) is above 200-day average (1781.4) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (2024.0) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
GOOD YEAR! Stock gained 41.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 63,253 vs down days: 23,550. Ratio: 2.69x
RSI
3/5
NEUTRAL! RSI at 41.6 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 71.9% of 52W range - positive territory.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.3% (1 week), 7.9% (1 month), 0.9% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
CORONA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-10 | Concall PDF | |
| Q4FY262026-05-18 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262026-01-12 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - General · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORONA | ₹2,024.00 | 62.2 | 13.5% | 16.6% | 29.7% | +41.9% | 76 | BREAKDOWN | +29.9% | +32.5% | +21.9% | +19.5% |
| KOPRAN | ₹251.10 | 48.6 | 3.6% | 7.2% | -1.9% | +46.6% | 63 | CONSOLIDATING DOWN | -9.5% | -64.6% | +13.9% | -34.2% |
| TTKHLTCARE | ₹1,016.60 | 18.7 | 8.3% | 5.9% | -53.2% | -8.9% | 59 | BREAKDOWN | +63.8% | -2.3% | +13.8% | +18.2% |
| NGLFINE | ₹2,925.00 | 30.2 | 10.7% | 21.8% | 32.9% | +103.5% | 85 | BREAKOUT | +100.0% | +36.3% | +33.6% | -6.7% |
| SAIPARENT | ₹493.90 | 177 | 3.9% | 126.1% | 111.8% | +23.4% | 68 | APPROACHING RESISTANCE | +464.3% | -1,416.7% | +435.0% | -33.6% |
| SMSPHARMA | ₹444.60 | 39.6 | 11.4% | 19.3% | – | +62.7% | 72 | CONSOLIDATING DOWN | +2.0% | -36.1% | +5.6% | -13.0% |
| SENORES | ₹1,320.00 | 44.4 | 18.7% | 159.1% | 139.2% | +89.8% | 74 | APPROACHING RESISTANCE | +55.8% | -2.8% | +35.9% | +2.9% |
| SANOFI | ₹2,945.40 | 21 | 17.9% | -12.6% | -19.3% | -36.6% | 57 | APPROACHING RESISTANCE | +20.1% | -18.6% | +7.7% | -7.3% |
Data from TradeAlone · Updated daily
CORONA News
Corona Remedies Limited (corona) Q1 FY27: Revenue and PAT Growth Up 21.9% and 30.1% Y-o-y2026-07-31Corona Remedies Limited Launches India’s Most Advanced Eu-gmp Approved Women’s Hormone Manufacturing Facility2026-06-30Corona Remedies Limited (corona) Accelerates India and World Market Expansion with Eu-gmp Accreditations2026-05-28
